Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
CompanyBankAnalystCoverageOpinionWk chg4/29 cls
Dynavax Technologies Corp. (NASDAQ:DVAX)RBC Capital MarketsSimos SimeonidisDowngradeSector performer (from outperform)-26%$16.41
Simeonidis also lowered his target to $17 from $48 on continued concerns about Heplisav-B's safety. FDA extended its review by three months of a BLA for Heplisav-B to prevent HBV infection to review additional data submitted

Read the full 540 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE